NeoPharm seeks US FDA nod for IL13-PE38QQR to treat Idiopathic Pulmonary Fibrosis
Wednesday, January 06, 2010 16:00 IST Lake Bluff, Illinois
NeoPharm, Inc, has filed an investigational new drug application (IND) with the US Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).